leisure time -WSS

leisure time

author：explore 2025-10-04 11:35:36 - browse：24

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Patients, doctors press FTC to beef up hospital merger scrutiny

WSS

Senate bill would ban some hospital facility fees

David Liu startup to focus on CRISPR delivery

Questions and answers about ramping up H5N1 bird flu vaccine

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

FDA poised to publish guidelines for clinical trial diversity

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

entertainment

leisure time

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Hollywood unions extend contract negotiations for actors

Liver decline slowed by off

Hollywood unions extend contract negotiations for actors

Citing H5N1 threat, CDC urges peak flu monitoring this summer

How one medical school became remarkably diverse

Neurocrine congenital adrenal hyperplasia trial succeeds

DIEP, the 'gold standard' of breast reconstruction, is under threat

Eli Lilly CEO gives to Mike Pence presidential super PAC

focus

PBMs drew scrutiny in House hearing — and so did pharma

Patients, doctors press FTC to beef up hospital merger scrutiny

Questions and answers about ramping up H5N1 bird flu vaccine

Patients, doctors press FTC to beef up hospital merger scrutiny

Medicare to pay more for cardiac rehab in hospital outpatient clinics

For longer

hotspot

hotspot

focus

knowledge